본문 바로가기

Evaluation of the Dose-Response Relationship of Amlodipine and Losartan Combination in Patients with Essential Hypertension An 8-Week, Randomized, Double-Blind, Factorial, Phase II, Multicenter Study

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q3Scopus Q1
저널
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS12(1) · pp.35 · 2012
피인용
Web of Science 13
JCR IF
JCR 2011 1.77
ISSN
1175-3277

저자

  1. Park, Chang-Gyu고려대학교, Dept Cardiol, Guro Hosp, KO
  2. Youn, Ho-Joong가톨릭대학교, Catholic Med Ctr, Dept Cardiol, KO
  3. Chae, Shung-Chull경북대학교, Dept Cardiol, KO
  4. Yang, Joo-Young국민건강보험공단, Dept Cardiol, KO
  5. Kim, Moo-Hyun동아대학교, Med Ctr, Dept Cardiol, KO
  6. 홍택종부산대학교, 의과대학, 의학과, 내과학교실, KO
  7. Kim, Cheol Ho서울대학교, Bundang Hosp, Dept Cardiol, KO
  8. Kim, Jae Joong아산병원, Dept Cardiol, KO
  9. Hong, Bum-Kee연세대학교, Coll Med, Gangnam Severance Hosp, KO
  10. Jeong, Jin-Won원광대학교, Dept Cardiol, KO
  11. Park, Si-Hoon이화여자대학교, Dept Cardiol, KO
  12. Kwan, Jun인하대학교, Dept Cardiol, KO
  13. Choi, Young-Jin한림대학교, Med Ctr, Dept Cardiol, KO
  14. Cho, Seung-Yun연세대학교, Coll Med, Severance Hosp, KO

초록

Background: Despite recommendations for more intensive treatment and the availability of several effective treatments, hypertension remains uncontrolled in many patients. Objective: The aim of this study was to determine the dose-response relationship and assess the efficacy and safety of amlodipine or losartan monotherapy and amlodipine camsylate/losartan combination therapy in patients with essential hypertension. Methods: This was an 8-week, randomized, double-blind, factorial design, phase II, multicenter study conducted in outpatient hospital clinics among adult patients aged 18-75 years with essential hypertension. At screening, patients received placebo for 2-4 weeks. Eligible patients (n = 320) were randomized to one of eight treatment groups: amlodipine 5 mg or 10 mg, losartan 50 mg or 100 mg, amlodipine camsylate/losartan 5 mg/50 mg, 5 mg/100 mg, 10 mg/50 mg, or 10 mg/100 mg. Main Outcome Measures: The assumption of strict superiority was estimated using the mean change in sitting diastolic blood pressure (DBP) at 8 weeks. Safety was monitored through physical examinations, vital signs, laboratory test results, ECG, and adverse events. Results: The reduction in DBP at 8 weeks was significantly greater in patients treated with the combination therapies compared with the respective monotherapies for all specified comparisons except amlodipine camsylate/losartan 10 mg/100 mg versus amlodipine 10 mg. The incidence of adverse events in the group of patients treated with the amlodipine camsylate/losartan 10 mg/50 mg combination tended to be higher than for any other group (27.9%, 12/43); however, the effect was not statistically significant. Conclusion: Combination amlodipine camsylate/losartan (5 mg/50 mg, 5 mg/100 mg and 10 mg/50 mg) resulted in significantly greater BP lowering compared with amlodipine or losartan monotherapy, and was determined to be generally safe and tolerable in patients with essential hypertension.

키워드

ISOLATED SYSTOLIC HYPERTENSIONEND-POINT REDUCTIONHIGH BLOOD-PRESSURECARDIOVASCULAR MORBIDITYDIABETIC-NEPHROPATHYEFFICACYTOLERABILITYMONOTHERAPYSAFETYLIFE

식별자

WoS UID
000301278100004